Intellectual Property

Intellectual Property Portfolio

Three decades of invention. A validated portfolio of patents, trademarks, and proprietary methodologies spanning multiple sterilization and purification domains.

1996 — 2026

Thirty years of validated invention.

PuroGen 30 years, 1996 to 2026
Patent documentation and engineering blueprints on drafting table

Patent Portfolio

PuroGen's patent portfolio covers core system architectures, process methodologies, and chemical formulations across multiple sterilization and purification domains.

SteriFlex™

Patented VHP Sterilization Platform

Originally filed as part of PuroGen's programmable sterilization architecture

Claims Summary

Programmable vaporized hydrogen peroxide (VH₂O₂) sterilization system with adjustable dwell times, reagent dosing, vacuum parameters, and high-humidity capability. Claims cover the parametric control architecture, cycle optimization methodology, and integration with validation instrumentation.

SteriFlex™ parametric cycle architecture — five programmable process parameters across four sterilization phases

Applications

Terminal sterilization of medical devicesAllograft tissue processingPharmaceutical cleanroom decontaminationBiotechnology laboratory sterilization

TheBOX®

Patented Enclosed VHP Chamber

Patent granted for enclosed sterilization and infusion chamber design

Claims Summary

Enclosed sterilization chamber designed for VHP and Reactive Oxygen processing. Claims cover chamber architecture, gas distribution methodology, environmental control systems, and integration pathways for cleanroom, laboratory, and manufacturing environments.

TheBOX® enclosed chamber cycle — radial process diagram showing load, gas introduction, dwell, and decomposition stages

Applications

Enclosed sterilization for laboratory environmentsReactive Oxygen infusion processingAgricultural and biological specimen sterilizationCleanroom integration systems

T10⁶®

Two-Stage Non-Irradiated Tissue Sterilization Process

Developed 2006 — nearly two decades before industry adoption of non-irradiated methods

Claims Summary

Non-irradiated terminal sterilization of allograft tissue — a two-stage process comprising a proprietary cold sterilization stage and VHP terminal sterilization. Claims cover process parameters, methodology for achieving terminal sterilization while preserving osteoinductivity and growth factors, and the original scCO₂ embodiment developed in 2006.

T10⁶® two-stage process specification — cold sterilization and VHP terminal sterilization with preserved osteoinductivity

Applications

Allograft tissue sterilizationBone void filler processingSpinal fusion implant sterilizationBiological specimen preservation

Reactive Oxygen™

Advanced Oxidation Chemistry

Proprietary formulation with ongoing development

Claims Summary

Proprietary reactive oxygen species formulation for surface decontamination and environmental bioburden reduction. Process methodology encompasses generation, delivery, and controlled decomposition of reactive oxygen species for regulated applications.

Reactive Oxygen™ — ROS generation, vapor-phase delivery, oxidation, and decomposition cascade

Applications

Surface decontaminationEnvironmental bioburden reductionAgricultural sterilization and infusionCleanroom and laboratory environments

Registered Trademarks

PuroGen's trademark portfolio reflects the breadth of its commercial platform.

SteriFlex™

Trademark

TheBOX®

Registered

T10⁶®

Registered

Reactive Oxygen™

Trademark

PuroGen®

Registered

BoxPurify®

Registered

BoxInfuse®

Registered

Beyond Patents

Proprietary knowledge that cannot be replicated.

PuroGen's intellectual property extends beyond patents to include proprietary process parameters, validation methodologies, and formulation know-how developed over decades of regulated sterilization and purification work.

This institutional knowledge — the accumulated understanding of how materials behave under specific conditions, how regulatory requirements translate into process design, and how validation methodologies evolve across domains — represents an asset that cannot be replicated through reverse engineering or independent development.

IP Underpinning

The three operational departures that define PuroGen's platform — driven substrate penetration, a moisture operating range up to ~20% RH, and product-specific programmable cycle architecture — are not marketing claims. They are the subject matter of PuroGen's patent portfolio. The claims represent sustained original work at the bench, not technology acquired or adapted from third-party IP.

Three departures from conventional VHP

Interested in PuroGen's technology portfolio?

This portfolio is available to corporate development teams, technology licensing professionals, and strategic partners for confidential discussion.